{"id":620338,"date":"2022-10-10T17:30:02","date_gmt":"2022-10-10T17:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=620338"},"modified":"2022-10-10T17:30:02","modified_gmt":"2022-10-10T17:30:02","slug":"psoriatic-arthritis-market-to-register-stunning-growth-during-the-forecast-period-202232-asserts-delveinsight-key-companies-pfizer-abbvie-sun-pharma-ucb-biopharma-bristolmyers-squibb","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-to-register-stunning-growth-during-the-forecast-period-202232-asserts-delveinsight-key-companies-pfizer-abbvie-sun-pharma-ucb-biopharma-bristolmyers-squibb_620338.html","title":{"rendered":"Psoriatic Arthritis Market to Register Stunning Growth During the Forecast Period (2022-32) – Asserts DelveInsight | Key Companies – Pfizer, AbbVie, Sun Pharma, UCB Biopharma, Bristol-Myers Squibb"},"content":{"rendered":"
\n
\"Psoriatic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Psoriatic Arthritis market size is expected to increase in the coming years owing to the launch of biosimilars and biologics, the rise in the prevalence of Psoriatic Arthritis cases, and expedited R&D activities in the therapeutics domain.<\/div>\n

DelveInsight’s “Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Psoriatic Arthritis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Psoriatic Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Psoriatic<\/p>\n

Psoriatic Arthritis: An Overview<\/strong><\/p>\n

Psoriatic arthritis (PsA)<\/strong> is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Clinical manifestations vary greatly between patients. It can present with oligoarticular joint involvement that is typically asymmetric or as a polyarticular disease affecting five or more joints, usually with an asymmetric distribution similar to that of rheumatoid arthritis.<\/p>\n

The current practice relies on the individualizing choice of treatment by matching the most severely affected domains of the patients with the best available evidence of the efficacies of drugs for those domains. When patients do not respond to treatment, shifting and cycling through different options would be the rational steps.<\/em><\/p>\n

Psoriatic Arthritis Market Key Facts<\/strong><\/p>\n